Zamboni, M. M., da Silva, C. T. Jr., Baretta, R., Cunha, E. T. & Cardoso, G. P. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm. Med. 15, 29 (2015).
Murthy, P. et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology 8, e1554969 (2019).
Morgensztern, D., Waqar, S., Subramanian, J., Trinkaus, K. & Govindan, R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J. Thorac. Oncol. 7, 1485–1489 (2012).
American Thoracic Society. Management of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 162, 1987–2001 (2000).
Stathopoulos, G. T. & Kalomenidis, I. Malignant pleural effusion: tumor-host interactions unleashed. Am. J. Respir. Crit. Care Med. 186, 487–492 (2012).
Lievense, L. A. et al. Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression. J. Thorac. Oncol. 11, 1755–1764 (2016).
Donnenberg, A. D., Luketich, J. D. & Donnenberg, V. S. Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications. Oncotarget 10, 6456–6465 (2019).
Cornelissen, R. et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 193, 1023–1031 (2016).
Google Scholar
Murthy, V., Katzman, D. & Sterman, D. H. Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy. Clin. Respir. J. 13, 272–279 (2019).
Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11, 1993–2005 (2016).
Tseng, Y. H. et al. PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion. J. Thorac. Oncol. 13, 447–453 (2018).
Google Scholar
Ghanim, B. et al. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Sci. Rep. 10, 5784 (2020).
Google Scholar
Hassan, R. et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 5, 351–357 (2019).
Alley, E. W., Katz, S. I., Cengel, K. A. & Simone, C. B. II Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl. Lung Cancer Res. 6, 212–219 (2017).
Google Scholar
Bakker, W., Nijhuis-Heddes, J. M. & van der Velde, E. A. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol. Immunother. 22, 155–159 (1986).
Google Scholar
Yanagawa, H. et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol. Immunother. 45, 93–99 (1997).
Google Scholar
Sartori, S. et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J. Clin. Oncol. 22, 1228–1233 (2004).
Google Scholar
Goey, S. H. et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I–II study. Br. J. Cancer 72, 1283–1288 (1995).
Google Scholar
Donnenberg, A. D., Luketich, J. D., Dhupar, R. & Donnenberg, V. S. Treatment of malignant pleural effusions: the case for localized immunotherapy. J. Immunother. Cancer 7, 110 (2019).
Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).
Google Scholar
Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014).
Google Scholar
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
Google Scholar
Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor. Immun. Immunogenic Tumors Immun. 41, 843–852 (2014).
Google Scholar
Baird, J. R. et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 76, 50–61 (2016).
Google Scholar
Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269–278 (2019).
Google Scholar
Park, C. G. et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018).
Li, L. et al. Hydrolysis of 2’3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043–1048 (2014).
Google Scholar
Kato, K. et al. Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1. Nat. Commun. 9, 4424 (2018).
Onyedibe, K. I., Wang, M. & Sintim, H. O. ENPP1, an old enzyme with new functions, and small molecule inhibitors-A STING in the tale of ENPP1. Molecules 24 (2019).
Belli, S. I., van Driel, I. R. & Goding, J. W. Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5’-nucleotide phosphodiesterase). Eur. J. Biochem. 217, 421–428 (1993).
Google Scholar
Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
Google Scholar
Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
Google Scholar
Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).
Cerboni, S. et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J. Exp. Med. 214, 1769–1785 (2017).
Google Scholar
Chen, J. et al. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. J. Clin. Invest. 129, 4224–4238 (2019).
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 938 (2014).
Google Scholar
Laoui, D. et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun. 7, 13720 (2016).
Google Scholar
Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723 e714 (2017).
Google Scholar
Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519–528 (2016).
Google Scholar
Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18–27 (2017).
Google Scholar
Gattinoni, L. Memory T cells officially join the stem cell club. Immunity 41, 7–9 (2014).
Google Scholar
Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614 (2020).
Google Scholar
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
Google Scholar
Bosi, A. et al. Natural killer cells from malignant pleural effusion are endowed with a decidual-like proangiogenic polarization. J. Immunol. Res. 2018, 2438598 (2018).
Vacca, P. et al. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur. J. Immunol. 43, 550–561 (2013).
Google Scholar
Dahan, R. et al. FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28, 285–295 (2015).
Google Scholar
Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 family revisited. Annu Rev. Immunol. 23, 515–548 (2005).
Kinter, A. L. et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181, 6738–6746 (2008).
Google Scholar
Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Disco. 4, 674–687 (2014).
Google Scholar
Dhupar, R. et al. Characteristics of malignant pleural effusion resident CD8(+) T cells from a heterogeneous collection of tumors. Int. J. Mol. Sci. 21 (2020).
DeLong, P. et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol. Ther. 4, 342–346 (2005).
Google Scholar
Wu, M. F. et al. The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer. Cancer Immunol. Immunother. 70, 1435–1450 (2021).
Google Scholar
Guo, M. et al. Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci. Transl. Med. 11, eaat5690 (2019).
Google Scholar
Li, J., Yang, Y. & Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 158, 108–114 (2012).
Google Scholar
Liu, Y. et al. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nat. Commun. 10, 5108 (2019).
Google Scholar
